RNA drugs and nonviral nanocarriers in oncology - present status and emerging concepts

Achim Aigner1

  • 1Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, University of Leipzig. Germany.

Insights

Non-viral nanoparticles are crucial for delivering RNA therapeutics in oncology, overcoming challenges like poor stability. These advanced systems protect RNA drugs, enhancing their efficacy and paving the way for new cancer treatments.

Area of Science:

  • Biotechnology and Nanomedicine
  • Oncology Therapeutics
  • Molecular Biology

Background:

  • RNA molecules present novel therapeutic avenues in oncology, distinct from conventional drugs.
  • Key challenges for RNA therapeutics include poor stability and pharmacokinetics, limiting clinical application.
  • Non-viral nanoparticle formulations are essential for protecting, delivering, and internalizing RNA payloads.

Purpose of the Study:

  • To review various RNA classes as potential drug candidates for oncological applications.
  • To discuss different non-viral nanoparticle systems for efficient RNA formulation and delivery.
  • To explore the role of RNA therapeutics in both in vivo and ex vivo cell-based therapies.

Main Methods:

  • Comprehensive review of RNA classes: small interfering RNAs (siRNAs), small guide RNAs (sgRNAs), messenger RNAs (mRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs).
  • Analysis of diverse non-viral nanocarrier systems designed for RNA formulation.
  • Evaluation of RNA therapeutic strategies for loss-of-function, gain-of-function, and gene expression modulation.

Main Results:

  • Various RNA types (siRNA, mRNA, miRNA, etc.) offer diverse mechanisms for interfering with cancer pathways.
  • Nanoparticle systems demonstrate potential for tailored RNA delivery based on target organ, cell, and RNA type.
  • Non-viral systems are critical for ex vivo modification of immune cells, offering an alternative to viral methods.

Conclusions:

  • Non-viral nanoparticle systems are indispensable for realizing the clinical potential of RNA therapeutics in oncology.
  • Sophisticated nanocarriers are needed to deliver combination RNA therapies with diverse properties.
  • Advancements in non-viral delivery systems are key to overcoming current limitations in RNA-based cancer treatments.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Drug Delivery: Overview01:16

Drug Delivery: Overview

The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
422
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
314